- Gaelic Laboratories has acquired Athlone Laboratories, strengthening its manufacturing capabilities and expanding its position in the Beta-Lactam antibiotics market.
- The acquisition will retain Athlone’s workforce and management team, enhance operational efficiency, and support long-term growth for both companies.
Gaelic Laboratories has acquired Athlone Laboratories in a move aimed at strengthening its market position in the production of Beta-Lactam medicines. The company said the deal enhances manufacturing capabilities, supports supply chain efficiency and aligns with its long-term growth strategy within the pharmaceutical sector.
The acquisition brings together two established Irish manufacturers of oral dose Beta-Lactam products. Gaelic Laboratories stated that combining the companies’ complementary operations is expected to broaden product offerings and drive operational efficiencies. General Manager Brian Morrissey said: “The deal is expected to deliver multiple financial and operational benefits, including cost savings through manufacturing consolidation, revenue growth and increased regulatory advantages.”
Gaelic Laboratories will retain personnel at the Athlone site, including the current management team, to ensure operational continuity for partners, suppliers and customers. Morrissey will assume hierarchical responsibility over both organisations. He noted that the total workforce has more than doubled to around 120 employees following the acquisition and emphasised the company’s commitment to supporting highly skilled jobs in Ireland.
According to Gaelic Laboratories, existing product lines and customer contracts will continue without disruption. The company said future priorities include investment to expand manufacturing capabilities, optimise processes and diversify product portfolios. It also plans to align IT and compliance systems across both organisations to support operational integration.
